Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 5/20 | 0.43 |
| ▸ | WNT3A | P56704 | 5/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | MERTK | Q12866 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966560 | 0.97 | ACACB (0.41) | CTNNB1WNT3AACACBTAAR1SLC6A2 | |
| SCHEMBL5018746 | 0.90 | ACACB (0.48) | ACACBTAAR1CYP2D6NPC1POLB | |
| SCHEMBL19465751 | 0.87 | KCNH2 (0.46) | TAAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5023473 | 0.81 | CTNNB1 (0.46) | CTNNB1WNT3ACLK1DYRK1ADYRK1B | |
| SCHEMBL12775573 | 0.81 | TAAR1 (0.56) | TAAR1SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL13146611 | 0.81 | RAB9A (0.44) | CTNNB1WNT3AACACBCLK1DYRK1A | |
| SCHEMBL3518645 | 0.81 | KDM4E (0.46) | CTNNB1WNT3AACACBCLK1DYRK1A | |
| Hydrochloric Acid SCHEMBL27569568 | 0.81 | CTNNB1 (0.41) | CTNNB1WNT3AACACBCLK1DYRK1A | |
| SCHEMBL20397605 | 0.79 | SLC6A4 (0.45) | CTNNB1WNT3AACACBTAAR1SLC6A2 | |
| SCHEMBL16416836 | 0.79 | CTNNB1 (0.43) | CTNNB1WNT3ASLC6A4CLK1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| US-11725000-B2 | Apoptosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2023-08-15 | — | — | US | disclosed |
| US-RE49080-E1 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2022-05-24 | — | — | US | disclosed |
| US-9895389-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-9895389-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2018-02-20 | — | — | US | disclosed |
| US-9738655-B2 | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20140274921-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20120196813-A1 | GLYCOSIDE DERIVATIVE AND USES THEREOF | NOVARTIS AG (CH) | 2012-08-02 | — | — | US | disclosed |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2012-07-12 | — | — | US | disclosed |
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8163704-B2 | Glycoside derivatives and uses thereof | NOVARTIS AG (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-20080318957-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008141010-A2 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042925-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | CTNNB1 2680/4885WNT3A 2523/4885ACACB 847/4885 |
| US-20120178680-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | CTNNB1 2680/4885WNT3A 2523/4885ACACB 847/4885 |
| US-11725000-B2 | Apoptosis inhibitors | BAX, SDHA, SDHB | CTNNB1 3043/4885WNT3A 4131/4885ACACB 433/4885 |
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | SLC18A2, SLC6A19, SLC1A1 | CTNNB1 4569/4885WNT3A 4427/4885ACACB 331/4885 |
| US-20150141354-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | CTNNB1 2680/4885WNT3A 2523/4885ACACB 847/4885 |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | CTNNB1 4592/4885WNT3A 4794/4885ACACB 470/4885 |
| US-20080318957-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | CTNNB1 4592/4885WNT3A 4794/4885ACACB 470/4885 |
| US-20110171159-A1 | Glycoside Derivatives and Uses Thereof | SLC5A1, SLC5A2, SLC2A1 | CTNNB1 2680/4885WNT3A 2523/4885ACACB 847/4885 |
| US-20140274921-A1 | GLYCOSIDE DERIVATIVES AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | CTNNB1 2680/4885WNT3A 2523/4885ACACB 847/4885 |
| US-20070082908-A1 | Bicycle pyrazole derivative | DPP4, DPP7, DPP3 | CTNNB1 954/4885WNT3A 259/4885ACACB 2825/4885 |
| US-20120196813-A1 | GLYCOSIDE DERIVATIVE AND USES THEREOF | SLC5A1, SLC5A2, SLC2A1 | CTNNB1 2870/4885WNT3A 2581/4885ACACB 881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.